GleamWall
中文EN

KMDA KAMADA LTD IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1567529 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.1%
TTM net income YoY39.7%
TTM EPS YoY40.0%
Revenue 3-yr CAGR-0.1%
Net income 3-yr CAGR—

Margins

Gross margin42.3%
Operating margin14.5%
Net margin11.2%
FCF margin—
EBITDA margin15.4%

Returns

ROE7.6%
ROA5.4%
ROIC (approx.)12.1%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets29.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage30.36x

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio-1.4%
Payout ratio114.2%
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY20242024-12-31
Income statement
Revenue$180.46M$160.95M
Cost of revenue$104.05M$90.99M
Gross profit$76.41M$69.97M
R&D expense$12.99M$15.19M
SG&A expense$18.72M$15.70M
Operating income$26.23M$20.05M
Interest expense$864,000$660,000
Pretax income$23.47M$13.33M
Income tax$3.27M-$1.13M
Net income$20.20M$14.46M
EBITDA$27.87M$21.54M
EPS (basic)0.350.25
EPS (diluted)0.350.25
Weighted avg. shares (diluted)58.35M57.82M
Balance sheet
Cash & equivalents$75.47M$78.44M
Receivables$27.01M$21.55M
Inventory$84.94M$78.82M
Current assets$193.07M$184.35M
PP&E, netmay include right-of-use assets (IFRS)$41.37M$36.24M
Goodwill$30.31M$30.31M
Total assets$378.71M$372.25M
Current liabilities$47.39M$49.39M
Short-term debt$9.92M$10.18M
Total liabilities$109.64M$112.79M
Shareholders' equity$269.07M$259.46M
Shares outstanding57.69M57.51M
Cash flow statement
Operating cash flow$25.49M$47.59M
Investing cash flow-$9.84M-$10.74M
Financing cash flow-$18.34M-$13.91M
Depreciation & amortization$1.64M$1.49M
Stock-based compensation$845,000$874,000
Dividends paid$11.53M—

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.